Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

BACKGROUND: Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with gatipotuzumab in patients with TA-MUC1-positive recurrent ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledermann, J.A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R.L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., Sehouli, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685985/
https://www.ncbi.nlm.nih.gov/pubmed/34920291
http://dx.doi.org/10.1016/j.esmoop.2021.100311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685985/
https://www.ncbi.nlm.nih.gov/pubmed/34920291
http://dx.doi.org/10.1016/j.esmoop.2021.100311

Ejemplares similares